Neumora Therapeutics Inc (NMRA) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access NMRA Annual Balance Sheets →
Reviewing balance sheet data across recent quarters allows users to assess how Neumora Therapeutics Inc manages assets, liabilities, and equity through different cycles.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent116.83
Marketable Securities, Current SH0.00
Cash & Short-term Investments116.00
Prepaid Expense And Other Assets Current8.04
Total Current Assets124.87
Equipment/Property/Plant Net0.03
Other Assets, Noncurrent0.35
Restricted Cash Current-
Operating Lease Right Of Use Asset0.36
Total Assets125.25
Liabilities
Accounts Payable, Current AC4.15
Accrued Liabilities, Current AC23.33
Short-term Debt60.00
Total Current Liabilities27.78
Long-term debt52.91
Total Long-term Debt52.91
Other liabilities, Noncurrent0.04
Early Exercise Liability Current Portion-
Operating Lease Liability Current0.29
Total Liabilities80.73
Stockholders' Equity
Common Stock Value0.02
Additional Paid In Capital Common Stock1,325.19
Retained Earnings / Accumulated Deficit-1,280.69
Other Equity0.00
Common Stockholder's Equity44.52
Total Stockholder's Equity44.52
Liabilities & Stockholder's Equity125.25
4 historic quarters locked

Sign in to unlock the full Neumora Therapeutics Inc balance sheet history.

About Neumora Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-350370

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.